Kazrin inhibitors represent a class of small molecules or compounds designed to target a specific cellular protein known as Kazrin. Kazrin itself is a relatively recently discovered protein with essential roles in cell adhesion and cell-cell junction formation. This protein is a key component of the desmosome, a cell-cell junction structure found in tissues like the skin, heart, and gastrointestinal tract. Desmosomes are crucial for maintaining tissue integrity and strength by facilitating strong adhesive connections between adjacent cells. Kazrin, as a structural component of desmosomes, helps to stabilize these junctions and is involved in regulating cell adhesion and migration processes.
The development of Kazrin inhibitors stems from a growing interest in understanding the molecular mechanisms underlying cell adhesion and tissue integrity. By inhibiting Kazrin's activity, researchers aim to investigate its precise role in desmosome function and cell adhesion, which could have implications for various physiological and pathological processes. These inhibitors are invaluable tools in the laboratory for studying cell biology, as they allow scientists to selectively manipulate Kazrin's function and explore its downstream effects on cell adhesion and tissue architecture.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Inhibits the tyrosine kinase activity of BCR-ABL, blocking the signaling pathways that promote cancer cell proliferation in chronic myeloid leukemia (CML). | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Targets multiple kinases, including Raf and VEGFR, disrupting tumor growth and angiogenesis in various cancers. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Selectively inhibits the epidermal growth factor receptor (EGFR) tyrosine kinase, impeding signaling pathways involved in cancer cell proliferation and survival. | ||||||
Vemurafenib | 918504-65-1 | sc-364643 sc-364643A | 10 mg 50 mg | $117.00 $423.00 | 11 | |
Specifically inhibits the mutated BRAF kinase in melanoma cells, preventing uncontrolled cell division and tumor growth. | ||||||
Erlotinib Hydrochloride | 183319-69-9 | sc-202154 sc-202154A | 10 mg 25 mg | $75.00 $121.00 | 33 | |
Blocks the EGFR tyrosine kinase, reducing cell growth and division in EGFR-mutated lung cancer. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $420.00 | 32 | |
Dual inhibitor of EGFR and HER2 kinases, interfering with cancer cell proliferation and metastasis in breast cancer. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Targets multiple kinases, including BCR-ABL and Src, inhibiting cell signaling pathways in leukemia and solid tumors. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
Selectively inhibits CDK4 and CDK6, disrupting the cell cycle progression in hormone receptor-positive breast cancer. | ||||||
Ibrutinib | 936563-96-1 | sc-483194 | 10 mg | $156.00 | 5 | |
Irreversibly inhibits BTK in B-cell malignancies, disrupting the B-cell receptor signaling pathway and inhibiting cell survival. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $251.00 $500.00 $547.00 | 16 | |
Inhibits JAK1 and JAK2, interfering with cytokine signaling and reducing inflammation in myeloproliferative neoplasms. | ||||||